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Recent studies have identified both recessive and dominant forms of mitochondrial disease that result from ATAD3A variants. The reces-
sive form includes subjects with biallelic deletions mediated by non-allelic homologous recombination. We report five unrelated neo-
nates with a lethal metabolic disorder characterized by cardiomyopathy, corneal opacities, encephalopathy, hypotonia, and seizures
in whom amonoallelic reciprocal duplication at the ATAD3 locus was identified. Analysis of the breakpoint junction fragment indicated
that these 67 kb heterozygous duplications were likely mediated by non-allelic homologous recombination at regions of high sequence
identity in ATAD3A exon 11 and ATAD3C exon 7. At the recombinant junction, the duplication allele produces a fusion gene derived
from ATAD3A and ATAD3C, the protein product of which lacks key functional residues. Analysis of fibroblasts derived from two affected
individuals shows that the fusion gene product is expressed and stable. These cells display perturbed cholesterol andmitochondrial DNA
organization similar to that observed for individuals with severe ATAD3A deficiency. We hypothesize that the fusion protein acts
through a dominant-negative mechanism to cause this fatal mitochondrial disorder. Our data delineate a molecular diagnosis for this
disorder, extend the clinical spectrum associated with structural variation at the ATAD3 locus, and identify a third mutational mecha-
nism for ATAD3 gene cluster variants. These results further affirm structural variant mutagenesis mechanisms in sporadic disease traits,
emphasize the importance of copy number analysis in molecular genomic diagnosis, and highlight some of the challenges of detecting
and interpreting clinically relevant rare gene rearrangements from next-generation sequencing data.Since its initial association with a neurological disorder,1 it
has become apparent that disruption of the ATAD3 cluster,
and more specifically ATAD3A (MIM: 612316), is a signifi-
cant cause of pediatric disease. Variants at this locus are
associated with a wide phenotypic spectrum, including
pontocerebellar hypoplasia,2 hereditary spastic para-
plegia,3 and a syndromic neurological disorder character-
ized by peripheral neuropathy, hypotonia, cardiomyopa-
thy, optic atrophy, cerebellar atrophy, and seizures:1
Harel-Yoon syndrome (HAYOS [MIM: 617183]). The
different phenotypes can be attributed to a spectrum of
disease-causing variants that includes bi-allelic hypomor-
phic variants, bi-allelic deletions, and monoallelic domi-
nant-negative missense variants. Here, we report two1Exeter Genomics Laboratory, Royal Devon and Exeter NHS Foundation Trust,
of Medicine and Health, University of Exeter, Exeter EX2 5DW, UK; 3Aging an
Oklahoma City, OK 73104, USA; 4Biodonostia Health Research Institute, 2001
ences, UCL Queen Square Institute of Neurology, Royal Free Campus, Londo
sah-Hebrew University Medical Center, Jerusalem 91120, Israel; 7Department o
State University School of Medicine, Children’s Hospital of Michigan, Detroi
College of Medicine, Houston, TX 77030, USA; 9South West Thames Regiona
London SW17 0QT, UK; 10St George’s University of London, London SW17
NHS Foundation Trust, Bristol BS2 8EG, UK; 12Department of Paediatric Card
UK; 13Clinical Genetics Service, NHSGrampian, Aberdeen Royal Infirmary, Abe
lational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle
Baylor College ofMedicine, Houston, TX 77030, USA; 16Human Genome Seque
Children’s Hospital, Houston, TX 77030, USA; 18MRC Centre for Neuromuscul
for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
20CIBERNED (Center for Networked Biomedical Research on Neurodegenera




 2020 The Authors. This is an open access article under the CC BY license (hde novo intergenic duplications in the ATAD3 cluster iden-
tified in five unrelated neonates with shared phenotypes
including corneal clouding, cardiomyopathy, hypotonia,
and white matter changes, thus expanding the genotype
spectrum of ATAD3-related disorders.
The ATAD3 cluster is composed of three paralogs with
extensive sequence homology, formed through tandem
segmental duplication: ATAD3A, ATAD3B (MIM:
612317), and ATAD3C (MIM: 617227). ATAD3A and
ATAD3B are protein-coding genes of near identical
sequence, differing primarily due to a stop-loss mutation
in ATAD3B that extends the protein by 62 amino acids;
ATAD3C is not known to be expressed. ATAD3A is a trans-
membrane ATPase, which is predicted to form hexamers,4Exeter EX2 5DW, UK; 2Institute of Biomedical and Clinical Science, College
d Metabolism Research Program, Oklahoma Medical Research Foundation,
4 San Sebastián, Spain; 5Department of Clinical and Movement Neurosci-
n NW3 2PF, UK; 6Department of Genetic and Metabolic Diseases, Hadas-
f Pediatrics, Division of Genetic, Genomic, and Metabolic Disorders, Wayne
t, MI 48201, USA; 8Department of Molecular and Human Genetics, Baylor
l Genetics Service, St George’s University Hospitals NHS Foundation Trust,
0RE, UK; 11Department of Clinical Genetics, University Hospitals Bristol
iology, University Hospitals Bristol NHS Foundation Trust, Bristol BS2 8BJ,
rdeen AB25 2ZA, UK; 14Wellcome Centre for Mitochondrial Research, Trans-
University, Newcastle upon Tyne NE2 4HH, UK; 15Department of Pediatrics,
ncing Center, Baylor College of Medicine, Houston, TX 77030, USA; 17Texas
ar Diseases, UCL Queen Square Institute of Neurology and National Hospital
; 19IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain;
tive Diseases, Ministry of Economy and Competitiveness, Institute Carlos
American Journal of Human Genetics 106, 1–8, February 6, 2020 1
ttp://creativecommons.org/licenses/by/4.0/).
Table 1. Clinical Features of Individuals with Duplication in ATAD3 Gene Cluster
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5
Sex male female male female male
Gestation term 38 weeks term 33þ3 weeks term
Apgars at birth 3 poor 1 5,8,9 1,0
Chronological
age at death
3 days 6 weeks 5 days 6 weeks 4 weeks








U ND ND ND ND
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U U U U U
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of brain volume (MRI);
abnormal MR spectroscopy
(lactate peak) on day 9
Contractures/
fetal akinesia
fetal akinesia ND contractures ND contractures
Edema/fetal
hydrops



























HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; SMA, spinal muscular atrophy; ND, not detected.
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ner and outer mitochondrial membranes5 in complex with
TSPO, CYP11A1, and OPA1.6 ATAD3 has also been
shown to interact with mitochondrial nucleoprotein com-
plexes and to play roles in mtDNA organization and repli-
cation.2,7,8 More recently it has been shown to interact
with Drp1/DNM1L to support Drp1-induced mitochon-
drial division,9 a process that drives mtDNA segrega-
tion.10,11 Concordantly, ATAD3 dysfunction and defi-
ciency have a wide range of effects on mitochondrial
structure and function, characterized by disturbed mito-
chondrial morphology and fission dynamics,3,6 loss of
cristae,12 perturbed mtDNA and cholesterol metabolism,
impaired mitochondrial steroidogenesis,2,13 and decreased
levels of some mitochondrial oxidative phosphorylation
(OXPHOS) components.12 It is not clear whether the
disruption to the innermitochondrial membrane, mtDNA,2 The American Journal of Human Genetics 106, 1–8, February 6, 202and OXPHOS complexes are due directly to the absence of
ATAD34,12 or whether they are consequences of changes to
membrane architecture resulting from an altered choles-
terol content2,13 or a combination of the two.
We report de novo ATAD3 duplications identified in five
unrelated neonates through exome sequencing. Clinical
exome sequencing failed to identify any alternative mo-
lecular diagnosis potentially causative of the phenotype,
which is characterized by seizures (four of the five neo-
nates) and fetal akinesia and contractures (in three case
subjects). A clinical summary is shown in Table 1 and
clinical case reports are detailed in the Supplemental
Note. Informed consent was obtained and all processes
adhered to local and national ethical standards. The
duplication in the ATAD3 cluster was also detected by
arrayCGH for those subjects studied (subjects four and
five). The duplication is predicted to be the product of0
Figure 1. NAHR between ATAD3C Exon 8
and ATAD3A Exon 11 Produces a Fusion
Gene, with Variants at Key Functional Resi-
dues within the ATPase Domain
Gene intron-exon structures are shown in
cartoon format; open boxes indicate UTRs
while closed boxes indicate coding regions.
Arrows following the gene name indicate
reading direction, and the first exon is
labeled. Genes are shown in their relative
position on chromosome 1 in a 50 to 30 direc-
tion from left to right.
(A) Nucleotide sequence identity between
ATAD3A (chr1:1512151–1534687:1) and
ATAD3C (chr1:1449689–1470158:1) in a
sliding 500 bp window. ATAD3A and
ATAD3C exon positions are represented
below according to their relative position
within the KAlign alignment; this includes
alignment gaps. The 398 bp region of
100% sequence identity is marked in yellow.
(B) Reference arrangement of the ATAD3
cluster showing the exon structures of
ATAD3C (purple), ATAD3B (orange), and
ATAD3A (green). The duplicated region is
highlighted in red.
(C) The reference arrangement of the ATAD3 cluster above the predicted configuration following duplication.
(D) The exon structure of the ATAD3A-C fusion gene, with exons 1–11 derived from ATAD3A (green) and exons 12–16 derived from
ATAD3C (purple). The ATPase domain is underlined (Asn347-Leu475; PFam PF00004), with the position of a key functional residue,
Arg466, indicated by an arrow.
(E) Amino acid sequence of the ATPase domain of ATAD3A (top) and the predicted amino acids sequence of the ATAD3A-C fusion pro-
tein (bottom). The green residues are derived from ATAD3A, while the purple residues are derived from ATAD3C. A vertical bar (|) indi-
cates an identical amino acid, a colon (:) indicates a strongly conservative amino acid change (score > 0.5 in PAM250 matrix), and a
period (.) indicates a weakly conservative amino acid change (score ¼ < 0.5 in PAM250 matrix). The sequences differ at seven positions.
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tween regions of high sequence homology in ATAD3C
and ATAD3A (Figure 1A) and encompasses ATAD3C
exons 8–12, ATAD3B, and ATAD3A exons 1–11 (Figures
1B, S1, and S2).
PCR and Sanger sequencing confirmed the presence of
the duplications, which showed a 1.2 kb proband-specific
amplicon (1.6 kb for subject four due to alternative primer
design; data not shown). No PCR product was amplified in
DNA derived from unaffected parents, consistent with a
de novo event, and proband-parent relationships were
confirmed for all case subjects during exome analysis.
The 50 end of the PCR amplicon was derived from ATAD3A
exon 10, while the 30 was derived from ATAD3C intron 7.
The breakpoints of the duplication identified in subject
four were found to differ from those identified in the other
case subjects. The duplications are considered functionally
equivalent as their protein products are predicted to be
identical, differing at a single intronic nucleotide.
These results are consistent with tandem duplication
without inversion, described as NC_000001.11(GRCh38):
1456616_1524663dup (subjects 1–3 and 5) and
NC_000001.11(GRCh38):1456890_1524937dup (subject
4). The duplications are predicted to maintain the copy-
number of ATAD3A and ATAD3C, duplicate ATAD3B, and
create a fusion gene, ATAD3A-C, composed of ATAD3A
(Uniprot: Q9NVI7-2, residues 1–405) and ATAD3C (Uni-
prot: Q5T2N8-1, residues 231–411) (Figures 1B and 1C).TheWe performedmultiple complementary in silico analyses
to characterize the effect of the duplication. Multiple
sequence alignment of ATAD3A (NC_000001.11
(GRCh38):1512151–1534687) and ATAD3C (NC_000001.11
(GRCh38):1449689–1470158) showed the genes have an
overall sequence identity of approximately 56%. The du-
plications occur at a 673 bp region with near-complete
sequence identity between ATAD3A and ATAD3C
(Figure 1A). In silico splicing analysis of ATAD3A-C showed
that the splice sites are maintained (Figure S3). Pairwise
alignment of ATAD3A (GenBank: NM_001170535.2;
Q9NVI7-2) and ATAD3A-C (Uniprot: Q9NVI7-2, residues
1–405, and Uniprot: Q5T2N8-1, residues 231–411)
primary amino acid sequences showed that they are
of identical length and differ at 29 residues (Figure S4).
Seven of the variants (p.Val450Ile, p.Asn454Cys,
p.Gln455His, p.Asp465Ala, p.Arg466Cys, p.Asn468Asp,
and p.Glu469Val) lie within the ATPase domain (residues
348–474; Pfam: PF00004) (Figure 1D, underline; Figure 1E),
while the remaining22arepresent outside of a known func-
tional domain (p.Glu482Ala, p.Phe489Leu, p.Asp490Asn,
p.Lys491Glu, p.Gln502Arg, p.Ser516Leu, p.Val518Ile,
p.Gly527Cys, p.Glu529Lys, and p.Glu545Lys) or within a
region of predicted intrinsic disorder (p.Thr556Ala,
p.Arg557Cys, p.Ala561Phe, p.Lys568Met, p.Cys570Arg,
p.Ala574Gly, p.Gly576Arg, p.Arg579Pro, p.Gly580Glu,
p.Pro583Gln, p.Ser584Pro, and p.Pro585Ser). DeepLoc
(v1.0) was used to predict the subcellular localization ofAmerican Journal of Human Genetics 106, 1–8, February 6, 2020 3
Figure 2. Elevated ATAD3 and Free
Cholesterol Levels in Fibroblasts Harboring
the ATAD3 Gene Cluster Duplication
(A) Level of ATAD3 in fibroblast of subject 1
compared to control subjects (Fiji ImageJ
densitometric analysis). The data are the
mean of n ¼ 6 independent experiments us-
ing three different control cell lines. Error
bars show 1 standard deviation (**p < 0.01;
Welch’s t test).
(B) A representative ATAD3 immunoblot
using a pan-specific antibody in fibroblasts.
Levels of GAPDH were used as indicators of
protein loading. The increased signal of the
upper band [B] is consistent with the dupli-
cation of ATAD3B. ATAD3A isoform 2 and
the predicted ATAD3A-C fusion protein
are of identical size; hence, the increased
signal of the lower band [A] is consistent
with the fusion gene being expressed and
stable.
(C) Chart showing mean filipin signal of
cells quantified by ImageJ. Subject 1: fibro-
blasts of an individual with the ATAD3
gene cluster duplication; Deletion: fibro-
blasts of an individual with a biallelic
ATAD3 gene cluster deletion (see Desai
et al.2 for details); U18: U18666A is an inhib-
itor of cholesterol trafficking; Filipin is a
fluorescent marker, which binds specifically
to unesterified cholesterol. Data are the re-
sults of 8 independent experiments for subject 1 and control subject(s) and n¼ 6 for the ‘‘deletion.’’ Error bars show 1 standard deviation
(***p < 0.001; **p % 0.01; one-way ANOVA).
(D) Representative images of filipin-stained cells. Scale bar 10 mm.
Please cite this article in press as: Gunning et al., Recurrent De Novo NAHR Reciprocal Duplications in the ATAD3 Gene Cluster Cause a Neu-
rogenetic Trait with Perturbe..., The American Journal of Human Genetics (2020), https://doi.org/10.1016/j.ajhg.2020.01.007ATAD3A and ATAD3A-C. The tool was able to correctly pre-
dict that ATAD3A is transported into the mitochondrial
membrane. There was no change in this prediction for
ATAD3A-C. Together, these analyses indicate that the
fusion transcript is likely to be correctly transcribed and
translated and maintain the signals necessary for native
subcellular localization.We nextmodeled the composition
of ATAD3 hexamers using a binomial distribution based on
two copies of ATAD3A and one copy of ATAD3A-C. It is pre-
dicted that 8.8% of ATAD3 hexamers would be comprised
solely of wild-type ATAD3Amonomers, while 91.2%would
contain at least one copy of the ATAD3A-C fusion protein
(Figure S5).
To experimentally assess the predictions of the in silico
analyses we amplified a 1.8 kb product by reverse tran-
scription PCR on RNA extracted from fibroblasts (subject
4), using a primer pair specific to ATAD3A and ATAD3C.
Sanger sequencing of this product showed a sequence
identical to the predicted ATAD3A-C transcript
(Figure S6). We found that the 50 region of the ATAD3A-C
fusion transcript corresponds to that of ATAD3A, splicing
isoform two. Western blotting showed that fibroblasts
(subject 1) harboring the duplication had higher expres-
sion of ATAD3, compared to controls (Figures 2A and
2B). The upper of the two bands is where ATAD3Bmigrates
and so the increased signal is attributed to the additional
copy of ATAD3B. As ATAD3A is not fully duplicated, the
increased signal of the lower band suggests that the4 The American Journal of Human Genetics 106, 1–8, February 6, 202ATAD3A-C protein product is expressed and stable.
ATAD3 is an established mitochondrial protein,7 and anti-
body labeling of ATAD3 in fibroblasts of subject 1 revealed
a distribution similar to control cells and to the mitochon-
drial outer membrane protein TOMM20 (Figure S7). There-
fore, both the duplicated ATAD3B and the ATAD3A-C
fusion gene protein product appear to be targeted to the
mitochondria.
Variants in bor, an ATAD3A homolog in Drosophila mela-
nogaster, are associated with a reduction in the number
of mitochondria and mitochondrial structural abnormal-
ities1 and bi-allelic ATAD3 cluster deletions have been
shown to cause mitochondrial structural abnormalities
and impaired cholesterol metabolism in human fibro-
blasts.2 Therefore, we assessed mitochondrial morphology
and cholesterol levels in our cellular models. In subject
1-derived fibroblasts, free-unesterified cholesterol assessed
by filipin staining was significantly higher than control
subjects and was similar to cells with pronounced ATAD3
deficiency caused by bi-allelic ATAD3 cluster deletions2
(Figures 2C and 2D). Many fibroblasts (subject 1) showed
aggregations of mitochondria, and swollen and rounded
organelles (Figure 3A; circled). Nevertheless, cells with an
extensive and interconnected mitochondrial network
were also apparent (Figure 3A). Immuno-staining for
DNA indicated that the swollen mitochondria contained
accumulations of mtDNA (Figure 3B; arrows). These fea-
tures are similar to those associated with ATAD3 cluster0
Figure 3. Abnormal Mitochondrial Morphology andmtDNAOr-
ganization in Cells with an ATAD3 Gene Cluster Duplication
(A) Confocal images showing the mitochondria of control cell
lines (C2) and fibroblasts from subject 1 (S1) labeled with an anti-
body to the outer mitochondrial membrane protein TOMM20
(red). Proportion of cells with clumped mitochondria for subject 1
versus 2 control subjects (n ¼ 2 independent experiments, R50
cells per cell line, per experiment).
(B) Fibroblast cells from control subject (C1) and subject 1 (S1)
labeled with an antibody against TOMM20 (red), a DNA antibody
(green), and DAPI (blue); arrows indicate mtDNA aggregation.
Scale bars 10 mm. Error bars show 1 standard deviation.
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tional and disrupts mitochondrial morphology and
mtDNA organization and causes abnormalities in cellular
cholesterol metabolism.
In addition to creating the ATAD3A-C fusion protein,
the duplication creates an additional copy of ATAD3B. To
determine whether this may have contributed to the sub-
jects’ phenotype, exome sequence data from all individ-
uals in the Deciphering Developmental Disorders (DDD)
cohort (n ¼ 32,369) were evaluated for the presence of du-
plications affecting the ATAD3 cluster. Excluding subject 5,
who was identified in this cohort, 61 individuals were
identified with likely monoallelic duplications intersecting
the ATAD3 cluster (size range of 67 kb–1.53 Mb), of which
48 affected only the ATAD3 cluster. All duplications were
found to fully encompass ATAD3B but did not intersectTheATAD3A. Duplications were carried either by unaffected
parents or probands whose clinical features were inconsis-
tent with a probable metabolic disorder, were above the
age of 1 year at their last clinical assessment, and were alive
at the point of recruitment. Confirmation testing was not
undertaken for the apparently benign duplications, and
the precise breakpoints have not been determined. Never-
theless, the presence of multiple ATAD3B duplications in
this study cohort suggests that the duplication of ATAD3B
and increased ATAD3B gene dosage alone is not causative
of this severe phenotype, but rather the NAHR-derived re-
combinant ATAD3A-C gene and novel protein product
generated by the de novo mutational event.
We have identified two de novo duplications within the
ATAD3 cluster in five unrelated individuals whose clinical
presentation suggested a metabolic disorder. ATAD3 gene
defects were recently recognized as a cause of human dis-
ease,1–3 accounting for a growing number of phenotypes
and cases. Dominant-negative ATAD3A missense variants
have been reported in individuals affected with hypotonia,
optic atrophy, axonal neuropathy, hypertrophic cardiomy-
opathy, and hereditary spastic paraplegia.1,3 Bi-allelic
ATAD3 cluster deletions result in a more severe phenotype
with pontocerebellar hypoplasia2,14,15 and death in the
majority of case subjects within the first week of life similar
to bi-allelic ATAD3A deletions.1 These case subjects with a
monoallelic ATAD3 gene cluster duplication extend the ge-
notype spectrum of ATAD3-related disorders.
The phenotype of the neonates with ATAD3 duplica-
tions shows overlap with the previously reported cases
associated with pathogenic variation at this locus noting
corneal clouding, cardiomyopathy, hypotonia, white mat-
ter changes, seizures, fetal akinesia, and contractures. All
subjects with duplication died within 6 weeks of life.
Although four neonates had low Apgar scores and required
intensive clinical management from birth, subject 4 was
born prematurely (33þ3 weeks), achieved high Apgar
scores, had a less severe perinatal course, and presented
3 weeks later with severe lactic acidosis (Table 1 and Sup-
plemental Note). The subjects did not present with
obvious signs of mitochondrial distress, and this study
highlights the importance of considering mitochondrial
genes even in atypical cases, such as these.
The ATAD3A-C fusion protein is uniquely associated
with the severe neonatal phenotype and therefore is likely
causal. It is expressed and stable (Figures 2A, 2B, and S6)
and has the correct subcellular localization (Figure S7).
The fusion protein differs from ATAD3A at 29 amino acid
residues within the C-terminal region, including a highly
conserved residue within the ATPase domain, p.Arg466Cys
(Figure 1D; arrow and Figure 1E). The equivalent residue is
conserved in all multimeric AAA-domain containing
ATPases and functions as an arginine finger, a trans-acting
residue that binds to the g-phosphate of ATP in the
neighboring monomer.16 Multiple recurrent missense
variants have been reported at the equivalent arginine
finger residue, Arg499, in SPAST (Figure 4) and causeAmerican Journal of Human Genetics 106, 1–8, February 6, 2020 5
Figure 4. Protein Modeling of ATAD3 Hexamer and 3D Align-
ment against SPAST ATPase Domain
(A) Hexameric structure of ATAD3A ATPase domain (amino acids
348–474), modeled in SwissModel using PDB: 6f0x (H. sapiens,
TRIP13) as a template. A single monomer is highlighted in violet.
(B) Single ATAD3A monomer (violet) aligned to H. sapiens SPAST
ATPase domain (blue).
(C) The ATAD3A arginine finger, Arg466 (yellow) which is
changed to a cysteine in the ATAD3A-C fusion gene, is overlaid
with the SPAST arginine finger (Arg499; orange).
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[MIM: 182601]).17,18 These variants have been shown to
result in the complete loss of SPASTATPase activity,19 lead-
ing to disease through a dominant-negative mechanism.
We suggest that the ATAD3 duplications described here
act through the same mechanism: through incorporation
of a non-functional monomer derived from the novel
fusion protein into more than 90% of ATAD3 hexamers
(Figure S5).
Our data suggest that the generation of the fusion pro-
tein causes this lethal neurological disorder through
disruption of mitochondrial and cholesterol metabolism
(Figures 2C, 2D, and 3). This reinforces the links between
ATAD3, cholesterol, and mtDNA metabolism. Consid-
ering the majority of the cholesterol in mitochondrial
membranes co-purifies with mtDNA,20 and increasing
or decreasing cholesterol availability markedly alters
mtDNA organization,2 then cholesterol dyshomeostasis
evidently disrupts mtDNA metabolism. ATAD3 has links
to cholesterol metabolism through partner proteins,6 The American Journal of Human Genetics 106, 1–8, February 6, 202TSPO, CYP11A1, and SPTLC.6,8 ATAD3 also co-purifies
with the mitochondrial protein synthesis machinery,
mtDNA, and mitochondrial cholesterol,7,8,20 and there
is evidence that the mitochondrial nucleoprotein
complexes are interlinked.21,22 Hence perturbed choles-
terol-containing micro-domains could be the common
factor linking all the features associated with ATAD3
deficiency.
Copy number variants (CNVs) pose a practical chal-
lenge in genomic analysis, in both their detection and
interpretation. Determining how to analyze and inter-
pret rare CNVs which intersect common benign CNVs
is not trivial. The high frequency of benign duplications
seen in the ATAD3 region coupled with high sequence
homology of the three genes means that pathogenic
duplications could potentially be missed. This study
highlights the importance of systematic CNV analysis,
particularly of genomic intervals prone to instability,
where a clinical presentation is consistent with a mono-
genic disorder.
The high frequency at which this specific ATAD3 dupli-
cationwas identified within this cohort suggests that for all
clinical suspicions of severe neonatal disorder of unknown
origin, negative for known mitochondrial variants and
mitochondrial nuclear genome panels, the ATAD3 locus
should be carefully evaluated for single nucleotide, copy-
number, and structural variants.Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2020.01.007.Acknowledgments
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Supplemental note – Case Reports 
Subject 1 was a male child born at term with normal antenatal screening. Fetal akinesia was 
reported at 38+3 weeks gestation. At birth the child was bradycardic, with Apgars of 3. The child was 
resuscitated, intubated and transferred to a neonatal unit. He showed severe neonatal 
encephalopathy with seizures, bilateral corneal opacities, small penis and undescended testes. Renal 
ultrasound showed pelvicalyceal dilation. Echocardiogram showed poor left ventricular function and 
thickened right ventricle with abnormal trabeculation of the right ventricular apex. ArrayCGH, 
Prader-Willi syndrome and spinomuscular atrophy testing were normal. Extensive metabolic 
investigation showed increased excretion of fumarate, malate, 2-ketoglutarate, 3-methylglutaconate 
and 3-methylglutarate. Death occurred at three days of age.  
Subject 2 was a female child born at 38 weeks with bilateral corneal opacities and bilateral single 
palmar creases. Antenatally, the neonate showed increased nuchal translucency but no evidence of 
trisomies 13, 18 or 21. There were poor Apgars at birth and the child was admitted to a neonatal 
intensive care unit. She developed hypoglycaemia and seizures; EEG analyses showed multifocal 
cerebral dysfunction; MRI brain showed simplified gyral patterning, temporal cysts and white matter 
changes. Cardiorespiratory arrest occurred at two weeks. Afterwards, cardiomyopathy was noted, 
acute renal failure and increasingly oedematous. Death occurred at six weeks of age.  
Subject 3 was a male child born at term with normal antenatal screening. Apgars of 1 at birth. The 
child was grossly hydropic and was resuscitated, intubated ventilated and transferred to a neonatal 
intensive care unit where abnormal cranial ultrasound with encephalopathy was noted. Death 
occurred at 5 days of age. Post-mortem studies showed an enlarged dilated heart with endocardial 
fibrosis and focal myocyte necrosis and widespread hypoxic brain damage. 
Subject 4 was a female child born at 33+3 weeks gestation who initially had mild feeding difficulties 
and hypotonia. She developed severe lactic acidosis at three weeks of life with worsening hypotonia 
requiring intubation. She was noted to have corneal clouding. She developed a significant pericardial 
effusion, persistent severe lactic acidosis, and death occurred at six weeks. During that time, a 
number of studies were done. An EEG showed diffuse cerebral dysfunction. A brain MRI 
demonstrated diffuse bilateral abnormal subcortical, periventricular, and deep white matter. Brain 
MR spectroscopy demonstrated decreased N-acetyl aspartate peak, markedly increased lactate 
peak, and small glutamine-glutamate peak. An echocardiogram showed concentric left ventricular 
hypertrophy with severely decreased function. Metabolic evaluations and a chromosomal 
microarray were nondiagnostic, except for urine organic acids, which showed markedly increased 
lactic acid, moderately increased 2-hydroxybutyric acid, fumaric acid, and 3-hydroxyisobutyric acids. 
A 202 gene Mitochondrial Genome Plus Mitochondrial Focused Nuclear Gene Panel (GeneDx, 
Gaithersburg, MD) revealed a heterozygous maternally inherited likely pathogenic variant in DNM1L 
(c.1588C>T; p.(Arg530Ter)). A second DNM1L variant was not identified and this maternally-
inherited variant was therefore not considered causative. Electron transport chain enzyme studies 
on skin fibroblasts and very long chain fatty acids with plasmalogens on plasma and skin fibroblasts 
were normal. 
Subject 5 was a male child born at term by Neville Barnes forceps due to a poor cardiotocography. 
He was hypotonic with bradycardia and had no respiratory effort at birth, but responded to IPPV and 
chest compression, and was crying with good respiratory effort at 15 minutes. Dense bilateral 
corneal clouding was noted, and there were mild limb contractures, and glandular hypospadias. He 
had generalized seizures at 4 days of life, treated with phenobarbitone. Respiratory effort was poor, 
and he was re-intubated. There may have been antenatal seizures, as daily episodes of fetal 
hiccoughing were described in the third trimester. An LP showed no evidence of infection, an EEG on 
 
 
day 6 showed a burst suppression pattern, and a brain MRI demonstrated abnormal white matter 
and a mild reduction in brain volume. MR spectroscopy showed an increased lactate peak. Multiple 
renal cysts were noted on ultrasound. An echocardiogram showed a small ventricular septal defect. 
Although he had no further seizures, he remained hypotonic, with poor respiratory effort and had 
intermittent metabolic acidosis with raised lactate. At 3 weeks of age, he developed poor perfusion 
with deteriorating metabolic acidosis and echocardiography revealed an enlarged, dilated heart with 
wall thickening and a pericardial effusion. Despite inotropic support, diuretics, and respiratory 
support he did not improve. He died at 4 weeks, 5 days of age.  Extensive metabolic investigation 
was undertaken in life, but was not conclusive. This included urine organic acids which were normal 
on day 3, but on day 22 there was increased lactate with moderate ketonuria along with a slight 
increase in malate and fumarate, possibly reflecting impaired mitochondrial function. At post 
mortem, cardiac muscle histochemistry showed a mosaic pattern of cytochrome c oxidase (COX) 
deficiency. A generally normal pattern was seen in skeletal muscle although there were some COX-
deficient blood vessels. COX (mitochondrial complex IV) enzyme activity was deficient in 





Figure S1. Exome read depth graph showing the ATAD3 duplication. Normalized read-depth over the ATAD3 
cluster for subject 1 (red line), compared to 1,634 samples previously analysed using the same capture library 
(Mean: Black Line; Range: light blue; 1 Standard Deviation: Dark Blue). The predicted extent of the duplication 


















Figure S2. ArrayCGH copy-number findings for subject 4. The predicted duplicated region is represented 
by a red bar. There remain data-points within the normal range (black) indicating that the 







Figure S3. In silico splicing prediction of the ATAD3A-C fusion gene. Splicing prediction for the ATAD3A-C 
fusion gene, using the (1) SpliceSiteFinder-like, (2) MaxEntScan, (3) Human Splicing Finder algorithms. ATAD3A 
exon 11 and ATAD3C exon 7 are homologous. The plot shows that ATAD3C retains the splice sites necessary 
for correct mRNA processing.  
 
  






































Figure S4. Amino acid sequence alignment of ATAD3A and ATAD3A-C. The predicted amino acid 
sequence of the ATAD3A-C fusion protein (green and purple) aligned against ATAD3A (black). A bar ('|') 
indicates an identical amino acid, a colon (':') indicates a strongly conservative amino acid change (score > 0.5 
in the PAM250 matrix) and a period ('.') indicates a weakly conservative amino acid change (score ≤ 0.5 in the 
PAM250 matrix). The green residues are derived from the ATAD3A gene, while the purple residues are derived 
from ATAD3C. The sequences are of identical length and differ at 29 amino acid positions (highlighted in 
yellow). Two ATP-binding residues of known function are outlined in red; Asn454 and Arg466. Underlining in 
the ATAD3A sequence indicates residues of the conserved protein kinase domain [p.Ile348 – p.Asp474; PFam 




                     ATAD3A exons 1 – 11                                        ATAD3C exons 8 - 12 
ATAD3A 
ATAD3A  1   MSWLFGINKGPKGEGAGPPPPLPPAQPGAEGGGDRGLGDRPAPKDKWSNFDPTGLERAAK 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Fusion  1   MSWLFGINKGPKGEGAGPPPPLPPAQPGAEGGGDRGLGDRPAPKDKWSNFDPTGLERAAK 
 
ATAD3A  61  AARELEHSRYAKDALNLAQMQEQTLQLEQQSKLKEYEAAVEQLKSEQIRAQAEERRKTLS 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Fusion  61  AARELEHSRYAKDALNLAQMQEQTLQLEQQSKLKEYEAAVEQLKSEQIRAQAEERRKTLS 
 
ATAD3A  121 EETRQHQARAQYQDKLARQRYEDQLKQQQLLNEENLRKQEESVQKQEAMRRATVEREMEL 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Fusion  121 EETRQHQARAQYQDKLARQRYEDQLKQQQLLNEENLRKQEESVQKQEAMRRATVEREMEL 
 
ATAD3A  181 RHKNEMLRVEAEARARAKAERENADIIREQIRLKAAEHRQTVLESIRTAGTLFGEGFRAF 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Fusion  181 RHKNEMLRVEAEARARAKAERENADIIREQIRLKAAEHRQTVLESIRTAGTLFGEGFRAF 
 
ATAD3A  241 VTDWDKVTATVAGLTLLAVGVYSAKNATLVAGRFIEARLGKPSLVRETSRITVLEALRHP 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Fusion  241 VTDWDKVTATVAGLTLLAVGVYSAKNATLVAGRFIEARLGKPSLVRETSRITVLEALRHP 
 
ATAD3A  301 IQVSRRLLSRPQDALEGVVLSPSLEARVRDIAIATRNTKKNRSLYRNILMYGPPGTGKTL 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Fusion  301 IQVSRRLLSRPQDALEGVVLSPSLEARVRDIAIATRNTKKNRSLYRNILMYGPPGTGKTL 
 
ATAD3A  361 FAKKLALHSGMDYAIMTGGDVAPMGREGVTAMHKLFDWANTSRRGLLLFVDEADAFLRKR 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Fusion  361 FAKKLALHSGMDYAIMTGGDVAPMGREGVTAMHKLFDWANTSRRGLLLFVDEADAFLRKR 
 
ATAD3A  421 ATEKISEDLRATLNAFLYRTGQHSNKFMLVLASNQPEQFDWAINDRINEMVHFDLPGQEE 
            |||||||||||||||||||||||||||||:|||..|||||||||..|:.||||||||||| 
Fusion  421 ATEKISEDLRATLNAFLYRTGQHSNKFMLILASCHPEQFDWAINACIDVMVHFDLPGQEE 
 
ATAD3A  481 RERLVRMYFDKYVLKPATEGKQRLKLAQFDYGRKCSEVARLTEGMSGREIAQLAVSWQAT 
            |.||||||.::||||||||||:|||||||||||||.|:||||||||.|:||||||||||| 
Fusion  481 RARLVRMYLNEYVLKPATEGKRRLKLAQFDYGRKCLEIARLTEGMSCRKIAQLAVSWQAT 
 
ATAD3A  541 AYASEDGVLTEAMMDTRVQDAVQQHQQKMCWLKAEGPGRGDEPSPS 586 
            ||||:||||||||||..|||.||||||.|.|||.|.||..||...| 
















Figure S5. Predicted binomial distribution of ATAD3A and ATAD3A-C in ATAD3 hexameric 
structures. (Left) The predicted binomial distribution of ATAD3A-C monomers in a homo-hexameric ATAD3 
quaternary structure, assuming a single copy of ATAD3A-C and two copies of ATAD3A. (Right) A cartoon 








predicted      atgtcgtggctcttcggcattaacaagggccccaagggtgaaggcgcggggccgccgccg 60 
RT-PCR         atGTCGTGGCTCTTCGGCATTAACAAGGGCCCCAAGGGTGAAGGCGCGGGGCCGCCGCCG 60 
               ************************************************************ 
 
predicted      cctttgccgcccgcgcagcccggggccgagggcggcggggaccgcgggttgggagaccgg 120 
RT-PCR         CCTTTGCCGCCCGCGCAGCCCGGGGCCGAGGGCGGCGGGGACCGCGGGTTGGGAGACCGG 120 
               ************************************************************ 
 
predicted      ccggcgcccaaggacaaatggagcaacttcgacCCCACCGGCCTGGAGCGCGCCgccaag 180 
RT-PCR         CCGGCGCCCAAGGACAAATGGAGCAACTTCGACCCCACCGGCCTGGAGCGCGCCGCCAAG 180 
               ************************************************************ 
 
predicted      gcggcgcgcgagctggagcactcgcgttatgccaaggacgccctgaatctggcacagatg 240 
RT-PCR         GCGGCGCGCGAGCTGGAGCACTCGCGTTATGCCAAGGACGCCCTGAATCTGGCACAGATG 240 
               ************************************************************ 
 
predicted      caggagcagacgctgcagttggagcaacagtccaagctcaaagagtatgaggccgccgtg 300 
RT-PCR         CAGGAGCAGACGCTGCAGTTGGAGCAACAGTCCAAGCTCAAAGAGTATGAGGCCGCCGTG 300 
               ************************************************************ 
 
predicted      gagcagctcaagagcgagcagatccgggcgcaggctgaggagaggaggaagaccctgagc 360 
RT-PCR         GAGCAGCTCAAGAGCGAGCAGATCCGGGCGCAGGCTGAGGAGAGGAGGAAGACCCTGAGC 360 
               ************************************************************ 
 
predicted      gaggagacccggcagcaccAGGCCAGGGCCCAGTATCAAGacaagctggcccggcagcgc 420 
RT-PCR         GAGGAGACCCGGCAGCACCAGGCCAGGGCCCAGTATCAAGACAAGCTGGCCCGGCAGCGC 420 
               ************************************************************ 
 
predicted      tacgaggaccaactgaagcagcagcaacttctcaatgaggagaatttacggaagcaggag 480 
RT-PCR         TACGAGGACCAACTGAAGCAGCAGCAACTTCTCAATGAGGAGAATTTACGGAAGCAGGAG 480 
               ************************************************************ 
 
predicted      gagtccgtgcagaagcaggaagccatgcggcgagccaccgtggagcggGAGATGGAGCTG 540 
RT-PCR         GAGTCCGTGCAGAAGCAGgaagccatgcggcgagccaccgtggagcgggagatggagctg 540 
               ************************************************************ 
 
predicted      CGGCACAAGaatgagatgctgcgagtggaggccgaggcccgggcgcgcgccaaggccgag 600 
RT-PCR         cggcacaagaatgagatgctgcgagtggaggccgaggcccgggcgcgcgccaaggccgag 600 
               ************************************************************ 
 
predicted      cgggagaatgcagacatcatccgcgagcagatccgcctgaaggcggccgagcaccgtcag 660 
RT-PCR         cgggagaatgcagacatcatccgcgagcagatccgcctgaaggcggccgagcaccgtcag 660 
               ************************************************************ 
 
predicted      accgtcttggagtccatcaggacggctggcaccttgtttggggaaggattccgtgccttt 720 
RT-PCR         accgtcttggagtccatcaggacggctggcaccttgtttggggaaggattccgtgccttt 720 
               ************************************************************ 
 
predicted      gtgacagactgggacaaagtgacagccacggtggctgggctgacgctgctggctgttggG 780 
RT-PCR         gtgacagactgggacaaagtgacagccacggtggctgggctgacgctgctggctgttggg 780 
               ************************************************************ 
 
predicted      GTCTACTCAGCCAAGAATGCcacgcttgtcgccggccgcttcatcgaggctcggctgggg 840 
RT-PCR         gtctactcagccaagaatgccacgcttgtcgccggccgcttcatcgaggctcggctgggg 840 
               ************************************************************ 
 
predicted      aagccgtccctagtgagggagacgtcccgcatcacggtgcttgaggcgctgcggcacccc 900 
RT-PCR         aagccgtccctagtgagggagacgtcccgcatcacggtgcttgaggcgctgcggcacccc 900 
               ************************************************************ 
 
predicted      atccaggtcagccggcggctcctcagtcgaccccaggacgcgctggagggtgttgtgctc 960 
RT-PCR         atccaggtcagccggcggctcctcagtcgaccccaggacgcgctggagggtgttgtgctc 960 
               ************************************************************ 
 
predicted      agtcccagcctggaagcacgggtgcgcgacatcgccatagcaacaaggaacaccaagaag 1020 
RT-PCR         agtcccagcctggaagcacgggtgcgcgacatcgccatagcaacaaggaacaccaagaag 1020 
               ************************************************************ 
 
predicted      aaccgcagcctgtacaggaacatcctgatgtacgggccaccaGGCaccgggAAGacgctg 1080 
RT-PCR         aaccgcagcctgtacaggaacatcctgatgtacgggccaccaggcaccgggaagacgctg 1080 






predicted      tttgccaagaaactcgccctgcactcaggcatggactacgccatcatgacaggcggggac 1140 
RT-PCR         tttgccaagaaactcgccctgcactcaggcatggactacgccatcatgacaggcggggac 1140 
               ************************************************************ 
 
predicted      gtggcccccatggggcgggaaggcgtgaccgccatgcacAAGCTCTTTGACTGGGCCAAT 1200 
RT-PCR         gtggcccccatggggcgggaaggcgtgaccgccatgcacaagctctttgactgggccaat 1200 
               ************************************************************ 
 
predicted      accagccggcgcggcCTCCTGCTCTTTGTGGATGAAGCGGACGCCTTCCTTCGGAAGCGA 1260 
RT-PCR         accagccggcgcggcctcctgctctttgtggatgaagcggacgccttccttcggaagcga 1260 
               ************************************************************ 
 
predicted      GCCACTgagaagataagcgaggacctcagggccacactgaacgccttcctgtaccgcacg 1320 
RT-PCR         gccactgagaagataagcgaggacctcagggccacactgaacgccTTCCTGTACCGCACG 1320 
               ************************************************************ 
 
predicted      ggccagcacagcaacaaattcatgctgatcctggccagctgccaccccgagcagttcgac 1380 
RT-PCR         GGCCAGCACAGCAACAAATTCATGCTGATCCTGGCCAGCTGCCACCCCGAGCAGTTCGAC 1380 
               ************************************************************ 
 
predicted      tgggccatcaatgcctgcatcgacgtgatggtccacttcgacctgccagggcaggaggag 1440 
RT-PCR         TGGGCCATCAATGCCTGCATCGACGTGATGGTCCACTTCGACCTGCCAGGGCAGGAGGAG 1440 
               ************************************************************ 
 
predicted      cgggcgcgcctggtgagaatgtatcttaacgagtatgttcttaagccggccacagaagga 1500 
RT-PCR         CGGGCGCGCCTGGTGAGAATGTATCTTAACGAGTATGTTCTTAAGCCGGCCACAGAAGGA 1500 
               ************************************************************ 
 
predicted      aagcggcgtctgaagctggcccagtttgactacgggaggaagtgcttagagatcgctcgg 1560 
RT-PCR         AAGCGGCGTCTGAAGCTGGCCCAGTTTGACTACGGGAGGAAGTGCTTAGAGATCGCTCGG 1560 
               ************************************************************ 
 
predicted      ctgacagagggcatgtcatGCCGGAAGATCGCACAGCTGGccgtgtcctggcaggccacg 1620 
RT-PCR         CTGACAGAGGGCATGTCATGCCGGAAGATCGCACAGCTGGCCGTGTCCTGGCAGGCCACG 1620 
               ************************************************************ 
 
predicted      gcgtatgcctccaaggacggggtcctgaccgaggccatgatggacgcctgcgtgcaagac 1680 
RT-PCR         GCGTATGCCTCCAAGGACGGGGTCCTGACCGAGGCCATGATGGACGCCTGCGTGCAAGAC 1680 
               ************************************************************ 
 
predicted      tttgtccagcagcaccagcagatgatgcgctggctgaagggggagaggcctgggcccgag 1740 
RT-PCR         TTTGTCCAGCAGCACCAGCAGATGATGCGCTggctgaagggggagaggcctgggcccgag 1740 
               ************************************************************ 
 
predicted      gacgagcaaccctcatcctga 1761 
RT-PCR         gacgagcaaccctcatcctga 1761 
               ********************* 
Figure S6. Nucleotide sequence alignment of a predicted ATAD3A-C fusion transcript and RT-PCR 
DNA product obtained from fibroblasts harboring the duplication. The predicted nucleotide sequence 
of the ATAD3A-C fusion transcript aligned with that for a reverse transcription PCR (RT-PCR) product obtained 










Figure S7. Antibody labelling of ATAD3 in fibroblasts reveals a similar distribution to control cells 
suggesting the ATAD3A-C fusion protein is targeted to mitochondria. Fibroblasts of control cells 
and subject 1 were labelled with anti-ATAD3 antibody (red) and DAPI (blue). Note the similar 
distribution to TOMM20 labeling [Figure 3A]. Co-staining cells with anti-ATAD3 and anti-TOMM20 
confirmed the ATAD3 signal was restricted to the mitochondria (data not shown). 
  





Cases 1-4 were referred for diagnostic trio exome sequencing due to a severe congenital 
developmental disorder. Case 5 was found through a manual analysis of the ATAD3 cluster in the 
Deciphering Developmental Disorders (DDD) study cohort (4) for all participants with an age of death 
under one year (n=66). Informed consent for testing and publication was obtained from all 
participants.  
Samples and genomic data  
Sample collection, DNA extraction, arrayCGH, exome library preparation, trio exome sequencing, 
variant calling and annotation were performed as described (5). DNA was extracted from cultured 
skin fibroblasts from subjects one and four. Exome read-depth and arrayCGH data were assessed 
manually. 
Confirmation of results by PCR and Sanger sequencing 
Primers were designed using Primer3 (National Human Genome Research Institute, USA). For case 
four, a forward primer specific to ATAD3A intron 9 (Chr1(GRCh38):g.1523723-1523743) and a 
reverse primer specific to ATAD3C intron 8 (Chr1(GRCh38):g.1457228-1457250) were designed. For 
the other cases, the forward primer was located in ATAD3A exon 10 
(NC_000001.11(GRCh38):g.1523875-1523893) and the reverse in ATAD3C intron 7 
(NC_000001.11(GRCh38):g.1456957-1456977). Products were visualized by electrophoresis on a 3% 
agarose gel and sequenced bi-directionally. 
Protein modelling 
The crystal structure of the ATAD3 ATPase domain has not been solved; the ATPase domains of 
ATAD3A [Ensembl: ENST00000378756.8; Uniprot:Q9NVI7-2] and the predicted fusion protein 
[residues 1-405 of Q9NVI7-2, residues 231-411 of Q5T2N8-1, “ATAD3A-C”] were modelled using 
SWISS-MODEL (6). The highest scoring structure [PDB: 6f0x; H. sapiens TRIP13] was used as a 
template for modelling both structures. The models were visualized in PyMol. 
In silico analyses 
In silico splicing analysis was performed on the splice junctions of ATAD3C exons 8-12, using the 
SpliceSiteFinder-like (1), MaxEntScan (2) and HSF (3) algorithms. The amino acid sequences of 
ATAD3A and ATAD3A-C were aligned using MUSCLE (7). The sequences were provided to DeepLoc 
(8) for analysis of the predicted subcellular localization. The genomic nucleotide sequences 
surrounding ATAD3A and ATAD3C were obtained from ENSEMBL and aligned using KAlign (9) to 
identify regions of homology. 
Cell culture  
Primary skin fibroblast cultures were obtained from subjects one and four, and healthy control 
individuals. Samples were confirmed free of mycoplasma based on the LookOut Mycoplasma PCR 
Detection Kit (Sigma). They were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, 
LifeTechnologies) supplemented with 10% fetal bovine serum (FBS, Hyclone/Sigma), 1% penicillin 





Reverse transcription, and polymerase chain reaction 
Total RNA was purified from fibroblasts obtained from subject 4 using TRIzol reagent (Life 
Technologies). cDNA was generated from 1 g of total RNA using the SuperScript IV First-Strand 
Synthesis System (Life technologies). The ATAD3A-C fusion gene was amplified using a forward 
primer specific to ATAD3A (NC_000001.11(GRCh38):g.1512269-1512287) and a reverse primer 
specific to ATAD3C (NC_000001.11(GRCh38):g.1468505-1468530).  
Western blot analysis, immunofluorescence and cell imaging 
Protein fractionation, transfer and immuno-detection were performed as described (10). Cells were 
lysed on ice in phosphate-buffered saline (PBS), n-dodecyl-D-maltoside (DDM), 1X protease inhibitor 
cocktail (Roche), and phosphatase inhibitor cocktail (Abcam) and 50 Units Benzonase (Millipore). 
Protein concentration was determined by DC protein assay kit (Biorad). Protein samples were 
prepared in 1× Laemmli loading buffer, heated at 42°C for 15 minutes and resolved on SDS-PAGE 
gels (Novex, Thermofisher Scientific). After electrophoresis, proteins were transferred to 
polyvinylidene fluoride membranes (PVDF, Millipore). Membranes were blocked with 5% non-fat dry 
milk in PBS with 0.1% (v/v) Tween-20 (PBST) and incubated overnight at 4°C with the primary 
antibodies: anti-GAPDH (1:20 000, Abcam), anti-ATAD3 (1:50 000, gift from John Walker and Jiuya 
He).   
Fibroblasts grown on coverslips were fixed with 4% paraformaldehyde in PBS for 15 minutes at 37°C. 
Cells were then washed three times for 5 minutes each with PBS before being permeabilized with 
0.3% Triton X-100 in PBS containing 5% fetal bovine serum (PBSS) for 5 minutes at room 
temperature. After permeabilization, samples were washed and blocked with PBSS for 1 hour at 
room temperature and later incubated with the indicated primary antibodies: anti-DNA (1:200-250, 
Progen), anti-TOMM20 (abcam 1:100-500), anti-ATAD3A (1:100, Novusbio) at 4°C overnight. 
Following washes, cells were incubated for 1 hour at room temperature with secondary antibody, 
after which coverslips were mounted on glass slides over ProLong Gold Antifade Reagent. 
Unesterified cholesterol in fibroblasts was stained with filipin, using a cholesterol assay kit (Abcam), 
detected by wide-field fluorescence microscopy and quantified using ImageJ. Images of filipin 
stained cells were acquired with a Nikon eclipse 80i epifluorescence microscope, using the NIS 
elements software. Filipin signals (pixels/unit area) were quantified in Image J, using the Huang 
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